U.S. Preventive Services Task Force banner
U.S. Preventive Services Task Force

You Are Here: U.S. Preventive Services Task Force > Topic Index > Screening for HIV > Final Recommendation Statement


Screening for HIV

U.S. Preventive Services Task Force Recommendation Statement

Release Date: April 2013


The U.S. Preventive Services Task Force (USPSTF) makes recommendations about preventive care services for patients without recognized signs or symptoms of the target condition.

It bases its recommendations on the evidence of both the benefits and harms of the service and an assessment of the balance. The USPSTF does not consider the costs of providing a service in this assessment.

The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize decision making to the specific patient or situation. Similarly, the USPSTF notes that policy and coverage decisions involve considerations in addition to the evidence of clinical benefits and harms.


This article was first published in Annals of Internal Medicine (Ann Intern Med 2013;30 Apr). Select for copyright and source information.

Contents

Summary of Recommendations and Evidence
Rationale
Clinical Considerations
Other Considerations
Discussion
Update of Previous Recommendation
Recommendations of Others
Members of the Task Force
References

Task Force Ratings
Strength of Recommendations and Quality of Evidence

Summary of Recommendations and Evidence

The USPSTF recommends that clinicians screen for HIV infection in adolescents and adults aged 15 to 65 years. Younger adolescents and older adults who are at increased risk should also be screened (A recommendation).

Go to the Clinical Considerations for more information about screening intervals.

The USPSTF recommends that clinicians screen all pregnant women for HIV, including those who present in labor who are untested and whose HIV status is unknown. (A recommendation)

Return to Contents

Rationale

Importance

An estimated 1.2 million persons in the United States are currently living with HIV infection, and the annual incidence of the disease is approximately 50,000 cases. Since the first cases of AIDS were reported in 1981, more than 1.1 million persons have been diagnosed and nearly 595,000 have died from the condition. Approximately 20% to 25% of individuals living with HIV infection are unaware of their positive status.

Detection

The USPSTF found convincing evidence that conventional and rapid HIV antibody tests are highly accurate in diagnosing HIV infection.

Benefits of Detection and Early Intervention

The USPSTF found convincing evidence that identification and treatment of HIV infection is associated with a markedly reduced risk for progression to AIDS, AIDS-related events, and death in individuals with immunologically advanced disease (defined as a CD4 count <0.200 × 109 cells/L). Adequate evidence shows that initiating combined antiretroviral therapy (ART) earlier (that is, at CD4 counts between 0.200 and 0.500 × 109 cells/L)—when individuals are more likely to be asymptomatic and detected by screening rather than clinical presentation—is also associated with reduced risk for AIDS-related events or death. The USPSTF found convincing evidence that the use of ART is associated with a substantially decreased risk for transmission from HIV-positive persons to uninfected heterosexual partners. Convincing evidence also shows that identification and treatment of HIV-positive pregnant women dramatically reduces rates of mother-to-child transmission. The overall benefits of screening for HIV infection in adolescents, adults, and pregnant women are substantial.

Harms of Detection and Early Intervention

The USPSTF found convincing evidence that individual antiretroviral drugs, drug classes, and combinations are all associated with short-term adverse events; however, many of these events are transient or self-limited, and effective alternatives can often be found. Although the long-term use of certain antiretroviral drugs may be associated with increased risk for cardiovascular and other adverse events, the magnitude of risk seems to be small. The overall harms of screening for and treatment of HIV infection in adolescents, adults, and pregnant women are small.

USPSTF Assessment

The USPSTF concludes with high certainty that the net benefit of screening for HIV infection in adolescents, adults, and pregnant women is substantial.

Clinical Considerations

Patient Population Under Consideration

These recommendations apply to adolescents, adults, and pregnant women.

Screening for HIV infection could begin at age 15 years unless an individual is identified at an earlier age with risk factors for HIV infection. Screening after age 65 years is indicated if there is ongoing risk for HIV infection, as indicated by risk assessment (for example, new sexual partners).

Assessment of Risk

According to estimates from the Centers for Disease Control and Prevention (CDC), men who have sex with men account for about 60% of HIV-positive persons in the United States (1). Among men living with HIV infection who were diagnosed at age 13 years or older, 68% of infections are attributed to male-to-male sexual contact, 8% are attributed to male-to-male sexual contact and injection drug use, and 11% are attributed to heterosexual contact. Among women living with HIV infection, 74% of infections are attributed to heterosexual contact and the remainder to injection drug use (1, 2). According to the CDC, heterosexual contact accounted for an estimated 25% of new HIV infections in 2010 and 27% of existing infections in 2009 (3, 4). Data from the CDC on HIV prevalence in different subpopulations are available at www.cdc.gov/hiv/topics/surveillance.

On the basis of HIV prevalence data, the USPSTF considers men who have sex with men and active injection drug users to be at very high risk for new HIV infection. Behavioral risk factors for HIV infection include having unprotected vaginal or anal intercourse; having sexual partners who are HIV-infected, bisexual, or injection drug users; or exchanging sex for drugs or money. Other persons at high risk include those who have acquired or request testing for other sexually transmitted infections (STIs). Patients may request HIV testing in the absence of reported risk factors. Individuals not at increased risk for HIV infection include persons who are not sexually active, those who are sexually active in exclusive monogamous relationships with uninfected partners, and those who do not fall into any of the aforementioned categories. The USPSTF recognizes that these categories are not mutually exclusive, the degree of sexual risk is on a continuum, and individuals may not be aware of their sexual partners' risk factors for HIV infection. For patients younger than 15 years and older than 65 years, it would be reasonable for clinicians to consider HIV risk factors among individual patients, especially those with new sexual partners. However, clinicians should bear in mind that adolescent and adult patients may be reluctant to disclose having HIV risk factors, even when asked.

Screening Intervals

The evidence is insufficient to determine optimum time intervals for HIV screening. One reasonable approach would be one-time screening of adolescent and adult patients to identify persons who are already HIV-positive, with repeated screening of those who are known to be at risk for HIV infection, those who are actively engaged in risky behaviors, and those who live or receive medical care in a high-prevalence setting. According to the CDC, a high-prevalence setting is a geographic location or community with an HIV seroprevalence of at least 1%. These settings include sexually transmitted disease (STD) clinics, correctional facilities, homeless shelters, tuberculosis clinics, clinics serving men who have sex with men, and adolescent health clinics with a high prevalence of STDs. Patient populations that would more likely benefit from more frequent testing include those who are known to be at higher risk for HIV infection, those who are actively engaged in risky behaviors, and those who live in a high-prevalence setting. Given the paucity of available evidence for specific screening intervals, a reasonable approach may be to rescreen groups at very high risk (see Assessment of Risk) for new HIV infection at least annually and individuals at increased risk at somewhat longer intervals (for example, 3 to 5 years). Routine rescreening may not be necessary for individuals who have not been at increased risk since they were found to be HIV-negative. Women screened during a previous pregnancy should be rescreened in subsequent pregnancies.

Screening Tests

The conventional serum test for diagnosing HIV infection is the repeatedly reactive immunoassay followed by confirmatory Western blot or immunofluorescent assay. The test is highly accurate (sensitivity and specificity, >99.5%), and results are available within 1 to 2 days from most commercial laboratories.

Rapid HIV testing may use either blood or oral fluid specimens and can provide results in 5 to 40 minutes. The sensitivity and specificity of the rapid test are also both greater than 99.5%; however, initial positive results require confirmation with conventional methods.

Other U.S. Food and Drug Administration–approved tests for detection and confirmation of HIV infection include combination tests (for p24 antigen and HIV antibodies) and qualitative HIV-1 RNA.

Treatment

No cure for chronic HIV infection currently exists. However, appropriately timed interventions in HIV-positive persons can reduce risks for clinical progression, complications or death from the disease, and disease transmission. Effective interventions include ART (specifically, the use of combined ART, defined as ≥3 antiretroviral agents used together, usually from ≥2 classes), immunizations, and prophylaxis for opportunistic infections.

Other Approaches to Prevention

The USPSTF recognizes that the most effective strategy for reducing HIV-related morbidity and mortality in the United States is primary prevention or avoidance of exposure to HIV infection. Condom use can also substantially decrease the risk for transmission of HIV and other STIs.

The USPSTF recommends high-intensity behavioral counseling to prevent STIs for all sexually active adolescents and for adults at increased risk for infection. More information can be found at www.uspreventiveservicestaskforce.org/uspstf/uspsstds.htm.

The Community Preventive Services Task Force has made several recommendations related to the prevention of HIV, AIDS, and other STIs, including person-to-person behavioral interventions (information and skill building to change knowledge, attitudes, beliefs, and self-efficacy) for men who have sex with men that can be implemented at the individual, group, or community level. It also recommends health provider notification and encouragement for HIV testing for sexual or needle-sharing partners of individuals diagnosed with HIV, as well as comprehensive risk reduction interventions in adolescents. More information can be found at www.thecommunityguide.org/hiv/index.html.

Other Resources

More information about HIV and AIDS is available at www.aids.gov and www.cdc.gov/hiv/default.htm.

The CDC's recommendations on HIV testing in adults, adolescents, and pregnant women in health care settings are available at www.cdc.gov/mmwr/preview/mmwrhtml/rr5514a1.htm. More information on HIV testing is available at www.cdc.gov/hiv/topics/testing/index.htm and www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm117922.htm.

Antiretroviral treatment guidelines are regularly updated and available at http://aidsinfo.nih.gov/guidelines.

Information about state-based HIV and AIDS hotlines is available at http://hab.hrsa.gov/gethelp/statehotlines.html.

Return to Contents

Other Considerations

Implementation

For populations in which the prevalence of undiagnosed HIV infection is known to be 0.1% or less (that is, ≤1 person in 1,000 is HIV-positive), where the potential benefit per person screened is low, it is reasonable to forgo routine HIV screening and instead screen on the basis of risk assessment. The CDC suggests that for populations in which the prevalence of HIV infection has not been documented, clinicians should initiate voluntary routine screening. If no HIV-infected patients are found after screening of approximately 4,000 patients, the upper limit of the 95% CI for prevalence is less than 0.1% (5) and routine screening may be discontinued and replaced with risk-based screening.

The USPSTF concurs with the CDC's recommendation that HIV screening should be voluntary and done only with the patient's knowledge and understanding. Patients should be informed orally or in writing that HIV testing will be performed unless they decline (opt-out screening). The USPSTF further concurs with the CDC's recommendation that before HIV testing, patients should receive an explanation of HIV infection and the meaning of positive and negative test results. Patients should also be offered the opportunity to ask questions and to decline testing. The CDC's recommendations on HIV testing in adults, adolescents, and pregnant women in health care settings are available at www.cdc.gov/mmwr/preview/mmwrhtml/rr5514a1.htm.

Cost-Effectiveness Analysis

The USPSTF's deliberations on grade recommendations for the effectiveness of clinical preventive services do not include cost or cost-effectiveness considerations. For policy context, however, the USPSTF reviewed some cost-effectiveness analyses published since its previous review (6-9). These analyses, which include downstream costs, support the cost-effectiveness of HIV screening in settings with low or average HIV prevalence. No studies directly compared universal versus targeted screening in low-prevalence populations or explicitly considered the potential long-term cardiovascular harms of ART.

Research Needs and Gaps

Individuals who begin ART tend to continue receiving it for an extended length of time. Better evidence is needed about the long-term harms of ART, including risks for cardiovascular and kidney disease. Further follow-up is necessary to better delineate potential long-term harms of ART initiation at higher CD4 cell counts. It would also be helpful to better elucidate the potential risks and long-term outcomes associated with in utero or perinatal exposure to ART. Antiretroviral treatment guidelines are regularly updated and available at http://aidsinfo.nih.gov/guidelines.

Direct evidence of the effectiveness of ART and behavioral counseling in reducing HIV transmission among men who have sex with men and other high-risk groups could also guide prevention and treatment strategies. Similarly, additional studies are needed to better define the optimum timing for treatment initiation. More research is needed about the differential effects of various HIV screening strategies on testing acceptability and uptake, linkage to and receipt of care, and harms. Information that could quantify any incremental benefits and harms of repeated HIV screening and identify ideal time intervals for rescreening in different populations would be useful.

Return to Contents

Discussion

Burden of Disease

Since the first cases of AIDS were reported in 1981, nearly 600,000 persons in the United States have died from the condition (10). Despite the decrease in AIDS cases and deaths after the introduction of ART, the CDC estimates that more than 1.1 million persons in the United States were living with HIV infection at the end of 2008, including 236,400 (20%) who did not know they were infected (10). Risk factors for HIV infection include having unprotected vaginal or anal intercourse with more than one partner; having sexual partners who are HIV-infected, bisexual, or injection drug users; exchanging sex for drugs or money; or engaging in injection drug use. According to the CDC, late diagnosis of HIV infection is common. Among persons with newly diagnosed HIV in 2008, 33% developed AIDS within 1 year of initial HIV diagnosis (1).

Scope of Review

In 2005, the USPSTF strongly recommended that clinicians screen for HIV in all adolescents and adults at increased risk for HIV infection, as well as all pregnant women (11). The USPSTF found good evidence that standard and rapid HIV screening tests are highly accurate and that most ART-associated adverse events, including metabolic disturbances associated with an increased risk for cardiovascular events, could be alleviated by changes in regimen or appropriate treatment. The USPSTF found good evidence that treatment of HIV-positive patients at immunologically advanced stages of disease (defined as a CD4 count <0.200 × 109 cells/L) results in markedly decreased risk for AIDS-related clinical events and death.

At that time, the USPSTF made no recommendation for or against routine HIV screening in adolescents and adults not at increased risk for HIV infection. This was based largely on several considerations. First, the USPSTF determined that HIV screening in patients without known risk factors would yield less than targeted screening. It estimated that the benefits of HIV screening would be substantial in high-risk patients and settings but small for populations not at increased risk for infection. Second, the USPSTF found insufficient evidence that initiation of ART in patients with CD4 counts greater than 0.200 × 109 cells/L would result in improved clinical outcomes. Third, the USPSTF found insufficient evidence that knowledge of HIV-positive status would actually result in decreased HIV transmission, either through initiation of highly active ART or reductions in risky behaviors.

For this update, the USPSTF reviewed new evidence on the effectiveness of treatments in HIV-infected persons with CD4 counts greater than 0.200 × 109 cells/L; effects of screening, counseling, and ART use on risky behaviors and HIV transmission risk; and long-term cardiovascular harms of ART.

Accuracy of Screening Tests

The 2005 USPSTF review found that standard and rapid HIV tests are highly accurate, with greater than 99.5% sensitivity and specificity (11). However, studies indicate that in lower-prevalence settings, rapid testing is associated with a lower positive predictive value (that is, a decreased proportion of positive results that are “true” positives), although results are generally confirmed before treatment.

Effectiveness of Early Detection and Treatment

The 2005 USPSTF review found convincing evidence that initiation of ART in HIV-positive patients with CD4 counts less than 0.200 × 109 cells/L markedly reduces AIDS-related morbidity and mortality. At that time, however, the USPSTF found inadequate evidence to conclude that initiation of ART in patients with higher CD4 cell counts would result in improved clinical outcomes.

To date, no randomized trials or observational studies have evaluated clinical outcomes among patients who are screened versus not screened for HIV infection, the yield of repeated versus one-time HIV screening, or the yield of different screening strategies (for example, risk-based vs. routine repeated screening). However, new evidence shows treatment benefits for HIV-positive patients with CD4 counts between 0.200 and 0.500 × 109 cells/L, which dramatically increases the pool of patients that could benefit from early detection.

Several studies show that initiation of ART at CD4 counts between 0.200 and 0.500 × 109 cells/L is associated with reduced risk for AIDS-related events or death. At this stage of HIV infection, patients are likely to be asymptomatic and detected via screening rather than clinical presentation.

The updated USPSTF review found two good-quality randomized trials (12, 13), one retrospective subgroup analysis from one randomized trial (14), and five observational studies (15-20) that evaluated clinical outcomes after initiation of ART at different CD4 cell count thresholds.

The randomized, controlled trial with the largest population was the HPTN 052 (HIV Prevention Trials Network 052) study (13), which compared mortality and clinical outcomes among 886 HIV-positive patients who received “early” ART (when CD4 counts were between 0.350 and 0.550 × 109 cells/L) with 877 HIV-positive patients who received “delayed” ART (after a decrease in CD4 count to ≤0.200 × 109 cells/L or symptom onset). This study was conducted in nine countries, with 54% of participants from Africa. It did not detect a significant difference in mortality between treatment groups. However, serious HIV-related clinical events, including death, were less likely among patients who received early treatment than among those who received delayed treatment (2.4 vs. 4.0 events/person-year; hazard ratio [HR], 0.59 [95% CI, 0.40 to 0.88]). According to the investigators, differences in the rates of serious HIV clinical events were driven largely by intergroup differences in the incidence of extrapulmonary tuberculosis, most of which were observed in India.

Another randomized, open-label, controlled trial conducted in Haiti compared 408 HIV-positive patients who received “early” ART (when CD4 counts were between 0.201 and 0.350 × 109 cells/L) with 408 HIV-positive patients who received “standard” treatment (when CD4 counts were ≤0.200 × 109 cells/L) (12). Deaths occurred more frequently in the standard treatment group than in the early treatment group (6% vs. 2%; HR, 4.0 [95% CI, 1.6 to 9.8]; P = 0.001), as did incident cases of tuberculosis (9% vs. 4%; HR, 2.0 [95% CI, 1.2 to 3.6]; P = 0.001). Because the study was not blinded, there may have been differential reporting and detection of nonfatal outcomes, which could affect progression to mortality. In addition, the study was conducted in a resource-poor setting with high rates of tuberculosis, malnutrition, and co-infection with tropical diseases, which limits the generalizability of the findings to the U.S. primary care population and may partially account for the large effect size. Accordingly, clinical benefits observed in the United States might not be as dramatic as those seen in these two trials.

Data from a third large randomized trial conducted primarily in Europe and North America (the SMART [Strategies for Management of Antiretroviral Therapy] study) (14) were reexamined in a post hoc exploratory analysis. In a retrospective subgroup analysis of 477 patients, initiation of ART at CD4 counts less than 0.250 × 109 cells/L was associated with increased risk for death or opportunistic disease compared with initiation at CD4 counts greater than 0.350 × 109 cells/L (2.7% vs. 0.5%; HR, 3.5 [95% CI, 1.3 to 9.6]; P = 0.02) (14). Because this question was not part of the original study plan, the investigators acknowledged that their findings could be less reliable and warranted further confirmation.

Fair-quality observational studies consistently found that initiation of ART at CD4 counts between 0.350 and 0.500 × 109 cells/L was associated with decreased risk for death (or a trend toward decreased risk) compared with deferred or no ART. Studies on initiation of ART at CD4 counts greater than 0.500 × 109 cells/L yielded less consistent results, as did studies of the combined outcome of death and AIDS-defining events. Limitations of these studies include insufficient information about baseline differences in patients who initiated ART at different CD4 cell count thresholds, suboptimum reporting of attrition, unblinded assessment of outcomes and analysis of data, and possible residual confounding.

Recent studies have also shown that early initiation of ART can reduce risk for HIV transmission to uninfected sexual partners. The HPTN 052 study enrolled 1,763 serodiscordant couples (that is, one partner was HIV-positive and the other was HIV-negative), most of which were heterosexual. Patients with HIV who had CD4 counts between 0.350 and 0.550 × 109 cells/L were randomly assigned to receive early (immediate) or delayed ART (after a decrease in CD4 count to ≤0.200 × 109 cells/L or symptom onset). At a median follow-up of 1.7 years, with most couples reporting 100% condom use, the incidence of seroconversion in HIV-negative partners was significantly lower among those whose HIV-positive partners had received early rather than delayed ART (0.3 vs. 2.2 events/100 person-years; HR, 0.11 [95% CI, 0.04 to 0.32]; P < 0.001). Seven observational studies of heterosexual transmission included in the USPSTF review were consistent with the results of this randomized trial. The potential effects of ART on HIV transmission have not been well-studied and could be attenuated in men who have sex with men or other high-risk populations, which account for most HIV-infected individuals in the United States.

Despite the potential effectiveness of ART as an HIV prevention strategy, it does not prevent the transmission of other STIs. Early diagnosis of HIV infection allows for risk reduction counseling and behavior change to reduce transmission of HIV and other STIs. In 2008, the USPSTF recommended high-intensity behavioral counseling to prevent STIs for all sexually active adolescents and for adults at increased risk for infection. The 2005 USPSTF review on screening for HIV included two systematic reviews that found consistent condom use to be associated with substantially reduced risk for sexual transmission of HIV infection; these findings have been confirmed in more recent observational studies. Self-reported condom use was associated with a 93% reduction in risk for heterosexual HIV transmission in a prospective cohort study (n = 476) (21). Inconsistent condom use was associated with an 8-fold increase in risk for seroconversion in another study of 1,927 serodiscordant heterosexual couples (adjusted relative risk, 8.4 [95% CI, 4.8 to 15]) (22). In one modeling analysis, earlier initiation of ART combined with modifications in risky sexual behavior reduced new infections by up to 65% (9).

Observational studies included in the current USPSTF review found that knowledge of HIV-positive status was associated with reductions in several high-risk behaviors, including having unprotected intercourse, having sex in exchange for money or drugs, having sex with commercial sex workers, using intravenous drugs, and needle sharing among injection drug users. Reductions in high-risk behaviors occurred in all populations studied, including men who have sex with men, injection drug users, and heterosexual persons. Similarly, observational studies also reported no clear association between initiation of ART and high-risk sexual behaviors.

In its deliberations about the age at which to begin screening, the USPSTF considered the prevalence of sexual activity and STDs among different age groups. According to CDC Youth Risk Behavior Surveillance data from 2011, nearly half of U.S. high school students had engaged in sexual intercourse and one third were currently sexually active (23). Of students who had been sexually active, one third had engaged in sexual intercourse before age 16 years (24). Although adolescents and young adults comprise one quarter of the sexually experienced population in the United States, they account for nearly one half of all cases of newly acquired STDs (25). As such, routine HIV screening starting at age 15 years would be reasonable. Because HIV prevalence markedly decreases after age 65 years, routine screening may not be necessary in older patients.

In its 2005 review, the USPSTF found convincing evidence that recommended regimens of ART resulted in significantly reduced rates of mother-to-child transmission. For its updated review, the USPSTF identified no new randomized trials of full-course combination ART during pregnancy in settings comparable to the United States. Three U.S. and European cohort studies published since 2005 found perinatal full-course triple ART to be associated with decreased risk for mother-to-child transmission (<1% to 2.4% among treated women vs. 9% to 22% among untreated women) (26-28).

Potential Harms of Screening and Treatment

The USPSTF's previous systematic review found that true-positive HIV test results may result in anxiety, depression, social stigma, changes in relationships with sexual partners, and discrimination (29). The USPSTF believes that patients who are diagnosed with HIV infection could benefit from counseling and ART. Because of the high specificity of conventional and rapid HIV testing strategies, false-positive test results are rare; reported rates of such results with conventional testing are 1 in 250,000 tests in low-prevalence populations (30). Evidence about potential consequences of receiving a false-positive HIV test result (for example, anxiety, psychological distress, or labeling) is limited and largely anecdotal (31). The actual consequences of initial false-positive rapid test results depend on whether patients are notified of these results before confirmatory testing. Most patients with initial positive results would not receive ART before confirmatory testing; one possible exception would be pregnant women in labor whose HIV status is unknown (described later). No studies directly evaluated psychological or other adverse effects associated with rapid versus conventional testing.

In the randomized trials comparing clinical outcomes among patients who received early versus standard ART, severe or life-threatening drug reactions did not occur more frequently in the early treatment group after exclusion of primary clinical end points (12, 13, 32). However, the early treatment group in the HPTN 052 study had ART-related adverse events more frequently (27% vs. 18%; P < 0.001), particularly grade 3 or 4 laboratory abnormalities, which the study investigators described as having unclear clinical significance (13).

Individual antiretroviral drugs, drug classes, and combinations are all associated with short-term adverse events; many of these events are transient or self-limited, and effective alternatives are often available. Longer-term use of ART regimens may increase the risk for cardiovascular and bone disease, as well as liver, renal, lipid, and glucose abnormalities (33). Aside from being potentially fatal, untreated HIV infection can contribute to these and other long-term complications (34).

A small increase in cardiovascular risk has been associated with specific protease inhibitors and nucleoside reverse transcriptase inhibitors in observational studies. The estimates of risk and the drugs implicated vary among studies. The 2005 USPSTF review included results from the large, ongoing DAD (Data Collection on Adverse Events of Anti-HIV Drugs) study, which found a 26% adjusted relative increase in the annual incidence of myocardial infarction during the first 4 to 6 years of exposure to ART (relative risk, 1.26 [95% CI, 1.12 to 1.41]; P < 0.001). In patients with more prolonged exposure to ART, the absolute risk for myocardial infarction was less than 0.6% and absolute event rates were low (3.5/1,000 person-years) (35). Subsequent analyses from the DAD study (36-38) and other cohort studies (39, 40) also report cardiovascular harms associated with ART.

In one study of rapid HIV testing of pregnant women in labor in a low-prevalence setting, infection was confirmed in 90% of women with positive test results. Because confirmatory testing is not available in time to inform emergent treatment decisions, a small percentage of HIV-negative mothers and their infants will potentially be exposed to the adverse effects of ART or surgical delivery.

Since the prior USPSTF review, several cohort studies of perinatal exposure to ART have reported increased risk for late preterm delivery, with no clear association between maternal use of ART and low birth weight, congenital anomalies, or differences in neurodevelopmental outcomes. Other studies reported echocardiographic abnormalities, mitochondrial dysfunction, anemia, and neutropenia among infants exposed to ART. However, the clinical significance of these findings remains unclear. The 11 studies included in this review were considered fair or poor quality.

Estimate of Magnitude of Net Benefit

The USPSTF recognizes that the most effective overall strategy for reduction of HIV-related morbidity and mortality in the United States is primary prevention or avoidance of exposure to HIV infection. The USPSTF concludes with high certainty that early detection and treatment of HIV transmission would result in substantial public health benefits in the United States. According to CDC estimates, more than 1.1 million persons were living with HIV infection in the United States at the end of 2008, including 236,400 (20%) who did not know they were infected. Screening for HIV infection in all adolescents and adults aged 15 to 65 years, persons at increased risk for infection, and pregnant women would allow for earlier and expanded detection of HIV infection, thus creating opportunities for earlier linkages to medical and behavioral interventions.

In the USPSTF's view, earlier initiation of ART in HIV-positive persons with CD4 counts less than 0.500 × 109 cells/L could substantially reduce disease burden in the United States. At an ART initiation threshold of a CD4 count of 0.500 × 109 cells/L, approximately 60 persons would need to be treated to prevent 1 death from HIV infection after 3 years. The USPSTF found good evidence that this intervention in this population could improve clinical outcomes and reduce sexual transmission. The USPSTF found adequate evidence that the harms of early detection and treatment of HIV infection are small and the clinical benefits of ART substantially outweigh potential risks of treatment in HIV-positive patients with CD4 counts less than 0.500 × 109 cells/L. The USPSTF also found convincing evidence that screening for HIV in pregnant women would confer substantial clinical benefits, with adequate evidence that the potential harms would be small.

The expected magnitude of benefit of HIV screening to an overall population is dependent, in part, on the frequency with which the disease occurs in that population. More individuals may benefit from routine HIV screening in a setting where HIV infection is more prevalent because the pool of affected individuals in which interventions could have a positive effect is larger. At the same time, an accurate assessment of the prevalence of HIV infection in a given geographic location may not be readily available, and in some cases, it can be difficult to reliably determine which individuals are actually at increased risk for HIV infection. Studies have shown that screening for HIV on the basis of risk factor assessment alone may miss 20% to 25% of HIV-positive individuals who report no risk factors.

On the basis of these findings, the USPSTF concludes with high certainty that early detection and treatment of HIV infection would result in substantial net benefit in the United States.

How Does Evidence Fit With Biological Understanding?

Late diagnosis of HIV infection is common. In 2008, one third of persons newly diagnosed with HIV developed AIDS within 1 year of diagnosis; according to the CDC, these persons had probably been infected for an average of 10 years before diagnosis. Moreover, 1 of 5 persons living with HIV infection did not know that they were infected (10). The long preclinical phase from HIV infection to symptom onset allows for the opportunity to screen, identify, and treat persons with HIV infection in order to reduce HIV-related morbidity and transmission. Reduction in viral load with ART can result in improved clinical outcomes for HIV-infected individuals and reduce transmission to uninfected persons.

Response to Public Comments

A draft version of this recommendation statement was posted for public comment on the USPSTF Web site from 19 November 2012 through 20 December 2012. In response to public comment, the USPSTF's final recommendation statement now includes a brief summary of its contextual review of cost-effectiveness analyses, clarifications of the potential harms that were examined in its systematic review, and an opt-out provision. The recommendation statement also includes more information about HIV prevalence and incidence in different population subgroups, HIV screening tests, and potential long-term harms of ART.

Return to Contents

Update of Previous USPSTF Recommendation

This updated recommendation reaffirms and expands the USPSTF's previous recommendations on HIV screening (11). In 2005, the USPSTF strongly recommended that clinicians screen for HIV in all adolescents and adults at increased risk for HIV infection, as well as all pregnant women. At that time, the USPSTF made no recommendation for or against routine HIV screening in adolescents and adults not at increased risk for HIV infection.

In addition to reaffirming its recommendation for HIV screening in persons at increased risk and pregnant women, the USPSTF expands its prior recommendation to include adolescents and adults aged 15 to 65 years who are not known to be at increased risk for HIV infection.

The USPSTF's expansion of its previous recommendation is based on studies published since 2005 that address previous evidence gaps. The USPSTF found that expanded HIV screening could identify a substantial number of persons with previously undiagnosed HIV infection, many of whom could benefit from initiation of ART, behavioral counseling, and other interventions. In particular, this recommendation includes new evidence that initiation of ART in HIV-infected persons with CD4 counts less than 0.500 × 109 cells/L could improve clinical outcomes and reduce sexual transmission.

Return to Contents

Recommendations of Others

In 2006, the CDC recommended routine voluntary HIV screening in all adolescents and adults aged 13 to 64 years regardless of other recognized risk factors, unless the prevalence of undiagnosed HIV infection has been documented to be less than 0.1% (41). The CDC also recommended opt-out HIV testing, meaning that all patients should be informed about and undergo testing unless they specifically decline, without a requirement for prevention counseling before screening in order to reduce barriers to testing. In 2009, the American College of Physicians endorsed the CDC's approach (5). The Infectious Diseases Society of America recommends routine HIV screening for all sexually active adults (42). The American Congress of Obstetricians and Gynecologists recommends routine opt-out screening in all women aged 19 to 64 years and targeted screening in women with risk factors outside of that age range (43). The American Academy of Pediatrics recommends offering routine HIV testing to all adolescents at least once by age 16 to 18 years when HIV prevalence is greater than 0.1% in the community, as well as testing of all sexually active adolescents and those with risk factors in low-prevalence settings (44). The American Academy of Family Physicians recommends that clinicians screen adolescents and adults aged 18 to 65 years for HIV infection, as well as younger adolescents and older adults who are at increased risk.

Return to Contents

Members of the U.S. Preventive Services Task Force

Members of the U.S. Preventive Services Task Force at the time this recommendation was finalized are Virginia A. Moyer, MD, MPH, Chair (American Board of Pediatrics, Chapel Hill, North Carolina); Michael L. LeFevre, MD, MSPH, Co-Vice Chair (University of Missouri School of Medicine, Columbia, Missouri); Albert L. Siu, MD, MSPH, Co-Vice Chair (Mount Sinai School of Medicine, New York, and James J. Peters Veterans Affairs Medical Center, Bronx, New York); Linda Ciofu Baumann, PhD, RN (University of Wisconsin, Madison, Wisconsin); Kirsten Bibbins-Domingo, PhD, MD (University of California, San Francisco, San Francisco, California); Susan J. Curry, PhD (University of Iowa College of Public Health, Iowa City, Iowa); Mark Ebell, MD, MS (University of Georgia, Athens, Georgia); Glenn Flores, MD (University of Texas Southwestern, Dallas, Texas); Francisco A.R. García, MD, MPH (Pima County Department of Health, Tucson, Arizona); Adelita Gonzales Cantu, RN, PhD (University of Texas Health Science Center, San Antonio, Texas); David C. Grossman, MD, MPH (Group Health Cooperative, Seattle, Washington); Jessica Herzstein, MD, MPH (Air Products, Allentown, Pennsylvania); Wanda K. Nicholson, MD, MPH, MBA (University of North Carolina School of Medicine, Chapel Hill, North Carolina); Douglas K. Owens, MD, MS (Veteran Affairs Palo Alto Health Care System, Palo Alto, and Stanford University, Stanford, California); William R. Phillips, MD, MPH (University of Washington, Seattle, Washington); Michael P. Pignone, MD, MPH (University of North Carolina, Chapel Hill, North Carolina); and Carolina Reyes, MD, MPH (Virginia Hospital Center, Arlington, Virginia). Former USPSTF members who contributed to the development of this recommendation include George Isham, MD, MS, and Timothy J. Wilt, MD, MPH.

For a list of current Task Force members, go to www.uspreventiveservicestaskforce.org/members.htm.

Return to Contents

References

1. Centers for Disease Control and Prevention. HIV Surveillance Report: Diagnoses of HIV Infection and AIDS in the United States and Dependent Areas, 2009. Atlanta, GA: Centers for Disease Control and Prevention; 2011. Accessed at http://www.cdc.gov/hiv/pdf/statistics_2009_HIV_Surveillance_Report_vol_21.pdf on 27 March 2013.
2. Centers for Disease Control and Prevention. HIV Surveillance Report: Diagnoses of HIV Infection and AIDS in the United States and Dependent Areas, 2010. Atlanta, GA: Centers for Disease Control and Prevention; 2012. Accessed at http://www.cdc.gov/hiv/library/reports/surveillance/2010/surveillance_Report_vol_22.html on 27 March 2013.
3. Centers for Disease Control and Prevention. Monitoring Selected National HIV Prevention and Care Objectives by Using HIV Surveillance Data—United States and 6 U.S. Dependent Areas—2010. Atlanta, GA: Centers for Disease Control and Prevention; 2012. Accessed at http://www.cdc.gov/hiv/library/reports/surveillance/2010/surveillance_Report_vol_17_no_3.html on 27 March 2013.
4. Centers for Disease Control and Prevention. Estimated HIV Incidence in the United States, 2007–2010. Atlanta, GA: Centers for Disease Control and Prevention; 2012. Accessed at http://www.cdc.gov/hiv/pdf/statistics_hssr_vol_17_no_4.pdf on 27 March 2013.
5. Qaseem A, Snow V, Shekelle P, Hopkins R Jr, Owens DK; Clinical Efficacy Assessment Subcommittee, American College of Physicians. Screening for HIV in health care settings: a guidance statement from the American College of Physicians and HIV Medicine Association. Ann Intern Med. 2009;150:125-31.
6. Paltiel AD, Walensky RP, Schackman BR, Seage GR 3rd, Mercincavage LM, Weinstein MC, et al. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med. 2006;145:797-806.
7. Sanders GD, Bayoumi AM, Holodniy M, Owens DK. Cost-effectiveness of HIV screening in patients older than 55 years of age. Ann Intern Med. 2008;148(12):889-903.
8. Sanders GD, Anaya HD, Asch S, Hoang T, Golden JF, Bayoumi AM, et al. Cost-effectiveness of strategies to improve HIV testing and receipt of results: economic analysis of a randomized controlled trial. J Gen Intern Med. 2010;25:556-63.
9. Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med. 2010;153:778-89.
10. Centers for Disease Control and Prevention. HIV surveillance—United States, 1981–2008. MMWR Morb Mortal Wkly Rep. 2011;60:689-93.
11. U.S. Preventive Services Task Force. Screening for HIV: recommendation statement. Ann Intern Med. 2005;143:32-7.
12. Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, Apollon S, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363(3):257-65.
13. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505.
14. Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, et al; Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197(8):1133-44.
15. Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, et al; HIV-CAUSAL Collaboration. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med. 2011;154(8):509-15.
16. Ray M, Logan R, Sterne JA, Hernández-Díaz S, Robins JM, Sabin C, et al; HIV-CAUSAL Collaboration. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS. 2010;24(1):123-37.
17. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al; NA-ACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815-26.
18. May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiébaut R, et al; Antiretroviral Therapy (ART) Cohort Collaboration. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS. 2007;21(9):1185-97.
19. Writing Committee for the CASCADE Collaboration. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Arch Intern Med. 2011;171(17):1560-9.
20. Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, et al; When To Start Consortium. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373(9672):1352-63.
21. Del Romero J, Castilla J, Hernando V, Rodríguez C, García S. Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study. BMJ. 2010;340:c2205.
22. Lu W, Zeng G, Luo J, Duo S, Xing G, Guo-Wei D, et al. HIV transmission risk among serodiscordant couples: a retrospective study of former plasma donors in Henan, China. J Acquir Immune Defic Syndr. 2010;55(2):232-38.
23. Eaton DK, Kann L, Kinchen S, Shanklin S, Flint KH, Hawkins J, et al; Centers for Disease Control and Prevention. Youth risk behavior surveillance—United States, 2011. MMWR Surveill Summ. 2012;61(4):1-162.
24. Cavazos-Rehg PA, Krauss MJ, Spitznagel EL, Schootman M, Bucholz KK, Peipert JF, et al. Age of sexual debut among US adolescents. Contraception. 2009;80(2):158-62.
25. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance, 2010. Atlanta: Centers for Disease Control and Prevention; 2011. Accessed at http://www.cdc.gov/std/stats10/default.htm on 16 October 2012.
26. Garcia-Tejedor A, Maiques V, Perales A, Lopez-Aldeguer J. Influence of highly active antiretroviral treatment (HAART) on risk factors for vertical HIV transmission. Acta Obstet Gynecol Scand. 2009;88(8):882-7.
27 Harris NS, Fowler MG, Sansom SL, Ruffo N, Lampe MA. Use of enhanced perinatal human immunodeficiency virus surveillance methods to assess antiretroviral use and perinatal human immunodeficiency virus transmission in the United States, 1999–2001. Am J Obstet Gynecol. 2007;197(3 Suppl):S33-41.
28. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. AIDS. 2008;22(8):973-81.
29. Chou R, Korthuis PT, Huffman LH, Smits AK. Screening for Human Immunodeficiency Virus in Adolescents and Adults. Evidence Synthesis No. 38. Rockville, MD: Agency for Healthcare Research and Quality; 2005.
30. Kleinman S, Busch MP, Hall L, Thomson R, Glynn S, Gallahan D, et al. False-positive HIV-1 test results in a low-risk screening setting of voluntary blood donation. Retrovirus Epidemiology Donor Study. JAMA. 1998;280:1080-5.
31. Gielen AC, O'Campo P, Faden RR, Eke A. Women's disclosure of HIV status: experiences of mistreatment and violence in an urban setting. Women Health. 1997;25(3):19-31.
32. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al; Partners in Prevention HSV/HIV Transmission Study Team. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375(9731):2092-8.
33. Reust CE. Common adverse effects of antiretroviral therapy for HIV disease. Am Fam Physician. 2011;83:1443-51.
34. Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013:1-9.
35. Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349(21):1993-2003.
36. Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al; DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723-35.
37. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, et al; DAD Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the DAD study: a multi-cohort collaboration. Lancet. 2008;371(9622):1417-26.
38. Rasmussen LD, Omland LH, Pedersen C, Gerstoft J, Kronborg G, Jensen J, et al. Risk of myocardial infarction in parents of HIV-infected individuals: a population-based cohort study. BMC Infect Dis. 2010;10:169.
39. Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis. 2011;53(1):84-91.
40. Obel N, Farkas DK, Kronborg G, Larsen CS, Pedersen G, Riis A, et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med. 2010;11(2):130-6.
41. Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al; Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1-17.
42. Lubinski C, Aberg J, Bardeguez AD, Elion R, Emmanuel P, Kuritzkes D, et al. HIV policy: the path forward—a joint position paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians. Clin Infect Dis. 2009;48(10):1335-44.
43. American College of Obstetricians and Gynecologists. ACOG committee opinion: routine human immunodeficiency virus screening. Obstet Gynecol. 2008;112(2 Pt 1):401-3.
44. Emmanuel PJ, Martinez J; Committee on Pediatric AIDS. Adolescents and HIV infection: the pediatrician's role in promoting routine testing. Pediatrics. 2011;128(5):1023-9.

Return to Contents

Copyright and Source Information

This document is in the public domain within the United States.

Source: This article was first published in Annals of Internal Medicine (Ann Intern Med 2013;30 Apr).

Disclaimer: Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

Financial Support: The USPSTF is an independent, voluntary body. The U.S. Congress mandates that the Agency for Healthcare Research and Quality support the operations of the USPSTF.

Potential Financial Conflicts of Interest: None disclosed.

Requests for Single Reprints: Reprints are available from the USPSTF Web site (wwww.uspreventiveservicestaskforce.org).

AHRQ Publication No. 12-05173-EF-3
Current as of April 2013


Internet Citation:

U.S. Preventive Services Task Force. Screening for HIV: Final Recommendation Statement. AHRQ Publication No. 12-05173-EF-3. http://www.uspreventiveservicestaskforce.org/uspstf13/hiv/hivfinalrs.htm


>

USPSTF Program Office   540 Gaither Road, Rockville, MD 20850